Patent obtained to use ‘Bryostatin-1' as an additive to organ transport and storage solutions, which may allow more organs to be made usable for transplantation.

Breakthrough Transplant Patent Granted to LSU Health Shreveport and Aphios Inventors

The LSU Health Shreveport Department of Molecular & Cellular Physiology and Aphios Corporation has obtained United States Patent No. 9,994,585 entitled “Transplantation Therapies,” for marine pharmaceutical ‘Bryostatin-1,’ which will be used as an additive to organ transport and storage solutions.

The use of this additive may allow nearly more organs to be made usable for transplantation by making marginal, or substandard, organs survive where they would not have before. Currently, many organs are not ultimately usable in transplantation and are considered less than ideal because they have exceeded the amount of time beyond which the organ would undergo failure. The current patent technology specifically blocks the mechanisms through which the body attacks the graft to prevent acute transplant failure. This innovative approach will have far-reaching impact on the entire transplantation industry.

J. Steven Alexander, PhD, Professor of Molecular & Cellular Physiology and Medicine at LSU Health Shreveport, working with April Carpenter Elrod, PhD, Assistant Professor of Health and Exercise Physiology at Ursinus College in Collegeville, Penn., and Dr. Trevor Castor at Aphios Corporation in Woburn, Mass., discovered that the treatment of blood vessels with Bryostatin-1, a compound derived from the marine bryozoans species Bugula neritina, stabilizes blood vessel cells called ‘endothelial’ cells allowing them to stop the infiltration by white cells, which should lead to better organ survival and many more organs being available. This will allow more organs to now be safely shipped trans-nationally and even internationally. Also important is that this drug does not need to be given to the recipient, but rather is only introduced to the donor organ during cold storage.

“The approach is nothing less than revolutionary and before very long we hope that it will be widely used as a main transplant solution,” said Dr. J. Steven Alexander about the new use patent.

Previously, Bryostatin-1 was researched for treating cancer for which it is not highly active, but consequently, has extensive human safety data.

About LSU Health Shreveport
LSU Health Sciences Center Shreveport is one of two Health Sciences Centers of the Louisiana State University System. LSUHSC- S is home to the School of Medicine, School of Graduate Studies and School of Allied Health Professions. More than 800 students are enrolled in the degree programs at any one time. Additionally, nearly 600 residents and fellows are trained each year. The primary mission of the LSU’s Health Sciences Center at Shreveport is to teach, heal, and discover, in order to advance the wellbeing of the region and beyond. At the heart of the LSUHSC-S is a strong faculty that include a number of nationally and internationally-acclaimed physicians and scientists. More than 600 strong, they lead our research efforts, educate our students and provide primary and specialty care to patients throughout the region. LSU Health Shreveport has strong community support, fostering a culture of diversity and inclusion that promotes mutual respect for all. For more information, visit

About Aphios Corporation
Aphios Corporation ( is a clinical stage biotechnology company developing green enabling technology platforms for improving drug discovery, manufacturing, delivery and safety, and enhanced natural therapeutics for health maintenance and disease prevention, and the treatment of cancers and supportive care, infectious diseases such as HIV, and CNS disorders such as Alzheimer’s disease and opioid addiction.


LSU Health Shreveport Contact:
Megan Strecker, Public Relations Coordinator
Office: 318-675-8789
Cell: 770-595-3052

Aphios Corportation Contact:
Trevor P. Castor, Ph.D., CEO
(001) 781-932-6933